Log in

NASDAQ:NUVA - NuVasive Stock Price, Forecast & News

$78.97
-0.43 (-0.54 %)
(As of 02/21/2020 02:13 AM ET)
Today's Range
$77.61
Now: $78.97
$79.98
50-Day Range
$75.95
MA: $78.12
$81.13
52-Week Range
$52.69
Now: $78.97
$81.91
Volume373,532 shs
Average Volume482,861 shs
Market Capitalization$4.11 billion
P/E Ratio86.78
Dividend YieldN/A
Beta1.2
NuVasive, Inc, a medical device company, develops and markets minimally disruptive surgical products and procedurally integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal products include Maximum Access Surgery, a minimally disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:NUVA
CUSIP67070410
Phone858-909-1800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.10 billion
Cash Flow$5.20 per share
Book Value$16.23 per share

Profitability

Net Income$12.47 million

Miscellaneous

Employees2,600
Market Cap$4.11 billion
Next Earnings DateN/A
OptionableOptionable

Receive NUVA News and Ratings via Email

Sign-up to receive the latest news and ratings for NUVA and its competitors with MarketBeat's FREE daily newsletter.


NuVasive (NASDAQ:NUVA) Frequently Asked Questions

What is NuVasive's stock symbol?

NuVasive trades on the NASDAQ under the ticker symbol "NUVA."

How were NuVasive's earnings last quarter?

NuVasive, Inc. (NASDAQ:NUVA) issued its quarterly earnings data on Thursday, February, 20th. The medical device company reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.09. The medical device company had revenue of $310.40 million for the quarter, compared to analyst estimates of $304.93 million. NuVasive had a net margin of 4.15% and a return on equity of 14.93%. NuVasive's revenue was up 7.7% on a year-over-year basis. During the same period in the previous year, the firm earned $0.69 EPS. View NuVasive's Earnings History.

What guidance has NuVasive issued on next quarter's earnings?

NuVasive issued an update on its FY20 earnings guidance on Thursday, February, 20th. The company provided EPS guidance of $2.55-2.65 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.60. The company issued revenue guidance of $1.21-1.24 billion, compared to the consensus revenue estimate of $1.23 billion.

What price target have analysts set for NUVA?

16 equities research analysts have issued twelve-month price targets for NuVasive's stock. Their forecasts range from $55.00 to $93.00. On average, they expect NuVasive's share price to reach $77.73 in the next year. This suggests that the stock has a possible downside of 1.6%. View Analyst Price Targets for NuVasive.

What is the consensus analysts' recommendation for NuVasive?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NuVasive in the last year. There are currently 1 sell rating, 6 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NuVasive.

What are Wall Street analysts saying about NuVasive stock?

Here are some recent quotes from research analysts about NuVasive stock:
  • 1. According to Zacks Investment Research, "NuVasive exited the third quarter of 2019 on a promising note, with earnings and revenues beating estimates. We are encouraged to note that the company witnessed solid revenue growth across its U.S. Spinal Hardware business, driven by increased surgeon adoption of lateral single-position surgery and X360 system. Robust sales figures in some of the key international markets, especially in the  EMEA region, buoy optimism. We are upbeat about the raised EPS guidance for 2019. Continued momentum across several recently-launched products within AMS portfolio is encouraging. In the past six months, NuVasive has outperformed its industry. On the flip side, the slight revenue decline within the U.S. Surgical Support and Biologics segments and contraction in adjusted operating margin were disappointing." (11/1/2019)
  • 2. Cantor Fitzgerald analysts commented, ": We maintain our Neutral rating on NUVA, but raise our 12- month PT to $61 from $50 as NUVA’s performance justifies multiple expansion. NUVA reported 1Q revenue of $274.8MM (+5.9% organic), beating FactSet consensus by $5.6MM. 40bp benefit from one-time NCS collections and a faster-than-expected benefit from West Carrollton, GM (72.9%) and OM (14.9%) were higher than expectations, driving an EPS beat of $0.12. A number of favorable one-time items make determining the true underlying performance challenging." (5/2/2019)

Has NuVasive been receiving favorable news coverage?

News coverage about NUVA stock has trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. NuVasive earned a coverage optimism score of 2.0 on InfoTrie's scale. They also assigned news articles about the medical device company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for NuVasive.

Are investors shorting NuVasive?

NuVasive saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 4,200,000 shares, an increase of 7.7% from the January 15th total of 3,900,000 shares. Based on an average daily trading volume, of 497,800 shares, the days-to-cover ratio is currently 8.4 days. Approximately 8.1% of the shares of the stock are short sold. View NuVasive's Current Options Chain.

Who are some of NuVasive's key competitors?

What other stocks do shareholders of NuVasive own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NuVasive investors own include Incyte (INCY), Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Medivation (MDVN), Starbucks (SBUX), Alibaba Group (BABA), Global Sources Ltd. (Bermuda) (GSOL), Intel (INTC), Celgene (CELG) and Gilead Sciences (GILD).

Who are NuVasive's key executives?

NuVasive's management team includes the folowing people:
  • Mr. J. Christopher Barry, CEO & Director (Age 46)
  • Mr. Matthew W. Link, Pres (Age 44)
  • Dr. Peter M. Leddy, Exec. VP of People & Culture (Age 56)
  • Mr. Rajesh J. Asarpota, Exec. VP & CFO (Age 52)
  • Mr. Jereme Sylvain, Chief Accounting Officer (Age 39)

Who are NuVasive's major shareholders?

NuVasive's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Anchor Capital Advisors LLC (2.41%), Victory Capital Management Inc. (1.84%), Victory Capital Management Inc. (1.48%), Eagle Asset Management Inc. (1.42%), Geode Capital Management LLC (1.38%) and Charles Schwab Investment Management Inc. (0.77%). Company insiders that own NuVasive stock include Gregory T Lucier, Matthew Link and Paul Mcclintock. View Institutional Ownership Trends for NuVasive.

Which institutional investors are selling NuVasive stock?

NUVA stock was sold by a variety of institutional investors in the last quarter, including Man Group plc, Champlain Investment Partners LLC, Victory Capital Management Inc., Thrivent Financial for Lutherans, AQR Capital Management LLC, Eagle Asset Management Inc., Fort Washington Investment Advisors Inc. OH and Alliancebernstein L.P.. Company insiders that have sold NuVasive company stock in the last year include Gregory T Lucier, Matthew Link and Paul Mcclintock. View Insider Buying and Selling for NuVasive.

Which institutional investors are buying NuVasive stock?

NUVA stock was bought by a variety of institutional investors in the last quarter, including Anchor Capital Advisors LLC, Panagora Asset Management Inc., Renaissance Technologies LLC, Victory Capital Management Inc., Copper Rock Capital Partners LLC, WCM Investment Management LLC, Bank of Montreal Can and UBS Group AG. View Insider Buying and Selling for NuVasive.

How do I buy shares of NuVasive?

Shares of NUVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is NuVasive's stock price today?

One share of NUVA stock can currently be purchased for approximately $78.97.

How big of a company is NuVasive?

NuVasive has a market capitalization of $4.11 billion and generates $1.10 billion in revenue each year. The medical device company earns $12.47 million in net income (profit) each year or $2.23 on an earnings per share basis. NuVasive employs 2,600 workers across the globe.View Additional Information About NuVasive.

What is NuVasive's official website?

The official website for NuVasive is http://www.nuvasive.com/.

How can I contact NuVasive?

NuVasive's mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-909-1800 or via email at [email protected]


MarketBeat Community Rating for NuVasive (NASDAQ NUVA)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  746 (Thanks for Voting!)
Underperform Votes:  625 (Thanks for Voting!)
Total Votes:  1,371
MarketBeat's community ratings are surveys of what our community members think about NuVasive and other stocks. Vote "Outperform" if you believe NUVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NUVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/21/2020 by MarketBeat.com Staff

Featured Article: Inverted Yield Curve

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel